

***COVID-19 no Brasil:
Os Múltiplos Olhares da Ciência
para Compreensão e Formas de
Enfrentamento***

4

***Luís Paulo Souza e Souza
(Organizador)***



***COVID-19 no Brasil:
Os Múltiplos Olhares da Ciência
para Compreensão e Formas de
Enfrentamento***

4

***Luís Paulo Souza e Souza
(Organizador)***

Editora Chefe

Profª Drª Antonella Carvalho de Oliveira

Assistentes Editoriais

Natalia Oliveira

Bruno Oliveira

Flávia Roberta Barão

Bibliotecária

Janaina Ramos

Projeto Gráfico e Diagramação

Natália Sandrini de Azevedo

Camila Alves de Cremona

Luiza Alves Batista

Maria Alice Pinheiro

Imagens da Capa

Shutterstock

Edição de Arte

Luiza Alves Batista

Revisão

Os Autores

2020 by Atena Editora

Copyright © Atena Editora

Copyright do Texto © 2020 Os autores

Copyright da Edição © 2020 Atena Editora

Direitos para esta edição cedidos à Atena Editora pelos autores.



Todo o conteúdo deste livro está licenciado sob uma Licença de Atribuição *Creative Commons*. Atribuição-Não-Comercial-NãoDerivativos 4.0 Internacional (CC BY-NC-ND 4.0).

O conteúdo dos artigos e seus dados em sua forma, correção e confiabilidade são de responsabilidade exclusiva dos autores, inclusive não representam necessariamente a posição oficial da Atena Editora. Permitido o *download* da obra e o compartilhamento desde que sejam atribuídos créditos aos autores, mas sem a possibilidade de alterá-la de nenhuma forma ou utilizá-la para fins comerciais.

Todos os manuscritos foram previamente submetidos à avaliação cega pelos pares, membros do Conselho Editorial desta Editora, tendo sido aprovados para a publicação.

A Atena Editora é comprometida em garantir a integridade editorial em todas as etapas do processo de publicação. Situações suspeitas de má conduta científica serão investigadas sob o mais alto padrão de rigor acadêmico e ético.

Conselho Editorial

Ciências Humanas e Sociais Aplicadas

Prof. Dr. Alexandre Jose Schumacher – Instituto Federal de Educação, Ciência e Tecnologia do Paraná

Prof. Dr. Américo Junior Nunes da Silva – Universidade do Estado da Bahia

Prof. Dr. Antonio Carlos Frasson – Universidade Tecnológica Federal do Paraná

Prof. Dr. Antonio Gasparetto Júnior – Instituto Federal do Sudeste de Minas Gerais

Prof. Dr. Antonio Isidro-Filho – Universidade de Brasília

Prof. Dr. Carlos Antonio de Souza Moraes – Universidade Federal Fluminense
Profª Drª Cristina Gaio – Universidade de Lisboa
Prof. Dr. Daniel Richard Sant’Ana – Universidade de Brasília
Prof. Dr. Deyvison de Lima Oliveira – Universidade Federal de Rondônia
Profª Drª Dilma Antunes Silva – Universidade Federal de São Paulo
Prof. Dr. Edvaldo Antunes de Farias – Universidade Estácio de Sá
Prof. Dr. Elson Ferreira Costa – Universidade do Estado do Pará
Prof. Dr. Eloi Martins Senhora – Universidade Federal de Roraima
Prof. Dr. Gustavo Henrique Cepolini Ferreira – Universidade Estadual de Montes Claros
Profª Drª Ivone Goulart Lopes – Istituto Internazionele delle Figlie de Maria Ausiliatrice
Prof. Dr. Jadson Correia de Oliveira – Universidade Católica do Salvador
Prof. Dr. Julio Candido de Meirelles Junior – Universidade Federal Fluminense
Profª Drª Lina Maria Gonçalves – Universidade Federal do Tocantins
Prof. Dr. Luis Ricardo Fernandes da Costa – Universidade Estadual de Montes Claros
Profª Drª Natiéli Piovesan – Instituto Federal do Rio Grande do Norte
Prof. Dr. Marcelo Pereira da Silva – Pontifícia Universidade Católica de Campinas
Profª Drª Maria Luzia da Silva Santana – Universidade Federal de Mato Grosso do Sul
Profª Drª Paola Andressa Scortegagna – Universidade Estadual de Ponta Grossa
Profª Drª Rita de Cássia da Silva Oliveira – Universidade Estadual de Ponta Grossa
Prof. Dr. Rui Maia Diamantino – Universidade Salvador
Prof. Dr. Urandi João Rodrigues Junior – Universidade Federal do Oeste do Pará
Profª Drª Vanessa Bordin Viera – Universidade Federal de Campina Grande
Prof. Dr. William Cleber Domingues Silva – Universidade Federal Rural do Rio de Janeiro
Prof. Dr. Willian Douglas Guilherme – Universidade Federal do Tocantins

Ciências Agrárias e Multidisciplinar

Prof. Dr. Alexandre Igor Azevedo Pereira – Instituto Federal Goiano
Profª Drª Carla Cristina Bauermann Brasil – Universidade Federal de Santa Maria
Prof. Dr. Antonio Pasqualetto – Pontifícia Universidade Católica de Goiás
Prof. Dr. Cleberton Correia Santos – Universidade Federal da Grande Dourados
Profª Drª Daiane Garabeli Trojan – Universidade Norte do Paraná
Profª Drª Diocléa Almeida Seabra Silva – Universidade Federal Rural da Amazônia
Prof. Dr. Écio Souza Diniz – Universidade Federal de Viçosa
Prof. Dr. Fábio Steiner – Universidade Estadual de Mato Grosso do Sul
Prof. Dr. Fágner Cavalcante Patrocínio dos Santos – Universidade Federal do Ceará
Profª Drª Girlene Santos de Souza – Universidade Federal do Recôncavo da Bahia
Prof. Dr. Jael Soares Batista – Universidade Federal Rural do Semi-Árido
Prof. Dr. Júlio César Ribeiro – Universidade Federal Rural do Rio de Janeiro
Profª Drª Lina Raquel Santos Araújo – Universidade Estadual do Ceará
Prof. Dr. Pedro Manuel Villa – Universidade Federal de Viçosa
Profª Drª Raissa Rachel Salustriano da Silva Matos – Universidade Federal do Maranhão
Prof. Dr. Ronilson Freitas de Souza – Universidade do Estado do Pará
Profª Drª Talita de Santos Matos – Universidade Federal Rural do Rio de Janeiro
Prof. Dr. Tiago da Silva Teófilo – Universidade Federal Rural do Semi-Árido
Prof. Dr. Valdemar Antonio Paffaro Junior – Universidade Federal de Alfenas

Ciências Biológicas e da Saúde

Prof. Dr. André Ribeiro da Silva – Universidade de Brasília
Profª Drª Anelise Levay Murari – Universidade Federal de Pelotas
Prof. Dr. Benedito Rodrigues da Silva Neto – Universidade Federal de Goiás
Profª Drª Débora Luana Ribeiro Pessoa – Universidade Federal do Maranhão
Prof. Dr. Douglas Siqueira de Almeida Chaves -Universidade Federal Rural do Rio de Janeiro
Prof. Dr. Edson da Silva – Universidade Federal dos Vales do Jequitinhonha e Mucuri
Profª Drª Eleuza Rodrigues Machado – Faculdade Anhanguera de Brasília
Profª Drª Elane Schwinden Prudêncio – Universidade Federal de Santa Catarina
Profª Drª Eysler Gonçalves Maia Brasil – Universidade da Integração Internacional da Lusofonia Afro-Brasileira
Prof. Dr. Ferlando Lima Santos – Universidade Federal do Recôncavo da Bahia
Profª Drª Gabriela Vieira do Amaral – Universidade de Vassouras
Prof. Dr. Gianfábio Pimentel Franco – Universidade Federal de Santa Maria
Prof. Dr. Helio Franklin Rodrigues de Almeida – Universidade Federal de Rondônia
Profª Drª Iara Lúcia Tescarollo – Universidade São Francisco
Prof. Dr. Igor Luiz Vieira de Lima Santos – Universidade Federal de Campina Grande
Prof. Dr. Jefferson Thiago Souza – Universidade Estadual do Ceará
Prof. Dr. Jesus Rodrigues Lemos – Universidade Federal do Piauí
Prof. Dr. Jônatas de França Barros – Universidade Federal do Rio Grande do Norte
Prof. Dr. José Max Barbosa de Oliveira Junior – Universidade Federal do Oeste do Pará
Prof. Dr. Luís Paulo Souza e Souza – Universidade Federal do Amazonas
Profª Drª Magnólia de Araújo Campos – Universidade Federal de Campina Grande
Prof. Dr. Marcus Fernando da Silva Praxedes – Universidade Federal do Recôncavo da Bahia
Profª Drª Maria Tatiane Gonçalves Sá – Universidade do Estado do Pará
Profª Drª Mylena Andréa Oliveira Torres – Universidade Ceuma
Profª Drª Natiéli Piovesan – Instituto Federaci do Rio Grande do Norte
Prof. Dr. Paulo Inada – Universidade Estadual de Maringá
Prof. Dr. Rafael Henrique Silva – Hospital Universitário da Universidade Federal da Grande Dourados
Profª Drª Regiane Luz Carvalho – Centro Universitário das Faculdades Associadas de Ensino
Profª Drª Renata Mendes de Freitas – Universidade Federal de Juiz de Fora
Profª Drª Vanessa Lima Gonçalves – Universidade Estadual de Ponta Grossa
Profª Drª Vanessa Bordin Viera – Universidade Federal de Campina Grande

Ciências Exatas e da Terra e Engenharias

Prof. Dr. Adélio Alcino Sampaio Castro Machado – Universidade do Porto
Prof. Dr. Carlos Eduardo Sanches de Andrade – Universidade Federal de Goiás
Profª Drª Carmen Lúcia Voigt – Universidade Norte do Paraná
Prof. Dr. Douglas Gonçalves da Silva – Universidade Estadual do Sudoeste da Bahia
Prof. Dr. Eloi Rufato Junior – Universidade Tecnológica Federal do Paraná
Profª Drª Érica de Melo Azevedo – Instituto Federal do Rio de Janeiro
Prof. Dr. Fabrício Menezes Ramos – Instituto Federal do Pará
Profª Dr. Jéssica Verger Nardeli – Universidade Estadual Paulista Júlio de Mesquita Filho
Prof. Dr. Juliano Carlo Rufino de Freitas – Universidade Federal de Campina Grande
Profª Drª Luciana do Nascimento Mendes – Instituto Federal de Educação, Ciência e Tecnologia do Rio Grande do Norte

Prof. Dr. Marcelo Marques – Universidade Estadual de Maringá
Profª Drª Neiva Maria de Almeida – Universidade Federal da Paraíba
Profª Drª Natiéli Piovesan – Instituto Federal do Rio Grande do Norte
Profª Drª Priscila Tessmer Scaglioni – Universidade Federal de Pelotas
Prof. Dr. Takeshy Tachizawa – Faculdade de Campo Limpo Paulista

Linguística, Letras e Artes

Profª Drª Adriana Demite Stephani – Universidade Federal do Tocantins
Profª Drª Angeli Rose do Nascimento – Universidade Federal do Estado do Rio de Janeiro
Profª Drª Carolina Fernandes da Silva Mandaji – Universidade Tecnológica Federal do Paraná
Profª Drª Denise Rocha – Universidade Federal do Ceará
Prof. Dr. Fabiano Tadeu Grazioli – Universidade Regional Integrada do Alto Uruguai e das Missões
Prof. Dr. Gilmei Fleck – Universidade Estadual do Oeste do Paraná
Profª Drª Keyla Christina Almeida Portela – Instituto Federal de Educação, Ciência e Tecnologia do Paraná
Profª Drª Miranilde Oliveira Neves – Instituto de Educação, Ciência e Tecnologia do Pará
Profª Drª Sandra Regina Gardacho Pietrobon – Universidade Estadual do Centro-Oeste
Profª Drª Sheila Marta Carregosa Rocha – Universidade do Estado da Bahia

Conselho Técnico Científico

Prof. Me. Abrãao Carvalho Nogueira – Universidade Federal do Espírito Santo
Prof. Me. Adalberto Zorzo – Centro Estadual de Educação Tecnológica Paula Souza
Prof. Dr. Adailson Wagner Sousa de Vasconcelos – Ordem dos Advogados do Brasil/Seccional Paraíba
Prof. Dr. Adilson Tadeu Basquerote Silva – Universidade para o Desenvolvimento do Alto Vale do Itajaí
Prof. Me. Alexsandro Teixeira Ribeiro – Centro Universitário Internacional
Prof. Me. André Flávio Gonçalves Silva – Universidade Federal do Maranhão
Profª Ma. Andréa Cristina Marques de Araújo – Universidade Fernando Pessoa
Profª Drª Andreza Lopes – Instituto de Pesquisa e Desenvolvimento Acadêmico
Profª Drª Andrezza Miguel da Silva – Faculdade da Amazônia
Profª Ma. Anelisa Mota Gregoleti – Universidade Estadual de Maringá
Profª Ma. Anne Karynne da Silva Barbosa – Universidade Federal do Maranhão
Prof. Dr. Antonio Hot Pereira de Faria – Polícia Militar de Minas Gerais
Prof. Me. Armando Dias Duarte – Universidade Federal de Pernambuco
Profª Ma. Bianca Camargo Martins – UniCesumar
Profª Ma. Carolina Shimomura Nanya – Universidade Federal de São Carlos
Prof. Me. Carlos Antônio dos Santos – Universidade Federal Rural do Rio de Janeiro
Prof. Ma. Cláudia de Araújo Marques – Faculdade de Música do Espírito Santo
Profª Drª Cláudia Taís Siqueira Cagliariari – Centro Universitário Dinâmica das Cataratas
Prof. Me. Clécio Danilo Dias da Silva – Universidade Federal do Rio Grande do Norte
Prof. Me. Daniel da Silva Miranda – Universidade Federal do Pará
Profª Ma. Daniela da Silva Rodrigues – Universidade de Brasília
Profª Ma. Daniela Remião de Macedo – Universidade de Lisboa
Profª Ma. Dayane de Melo Barros – Universidade Federal de Pernambuco
Prof. Me. Douglas Santos Mezacas – Universidade Estadual de Goiás

Prof. Me. Edevaldo de Castro Monteiro – Embrapa Agrobiologia
Prof. Me. Eduardo Gomes de Oliveira – Faculdades Unificadas Doctum de Cataguases
Prof. Me. Eduardo Henrique Ferreira – Faculdade Pitágoras de Londrina
Prof. Dr. Edwaldo Costa – Marinha do Brasil
Prof. Me. Eliel Constantino da Silva – Universidade Estadual Paulista Júlio de Mesquita
Prof. Me. Ernane Rosa Martins – Instituto Federal de Educação, Ciência e Tecnologia de Goiás
Prof. Me. Euvaldo de Sousa Costa Junior – Prefeitura Municipal de São João do Piauí
Profª Ma. Fabiana Coelho Couto Rocha Corrêa – Centro Universitário Estácio Juiz de Fora
Prof. Me. Felipe da Costa Negrão – Universidade Federal do Amazonas
Profª Drª Germana Ponce de Leon Ramírez – Centro Universitário Adventista de São Paulo
Prof. Me. Gevair Campos – Instituto Mineiro de Agropecuária
Prof. Me. Givanildo de Oliveira Santos – Secretaria da Educação de Goiás
Prof. Dr. Guilherme Renato Gomes – Universidade Norte do Paraná
Prof. Me. Gustavo Krahl – Universidade do Oeste de Santa Catarina
Prof. Me. Helton Rangel Coutinho Junior – Tribunal de Justiça do Estado do Rio de Janeiro
Profª Ma. Isabelle Cerqueira Sousa – Universidade de Fortaleza
Profª Ma. Jaqueline Oliveira Rezende – Universidade Federal de Uberlândia
Prof. Me. Javier Antonio Alborno – University of Miami and Miami Dade College
Prof. Me. Jhonatan da Silva Lima – Universidade Federal do Pará
Prof. Dr. José Carlos da Silva Mendes – Instituto de Psicologia Cognitiva, Desenvolvimento Humano e Social
Prof. Me. Jose Elyton Batista dos Santos – Universidade Federal de Sergipe
Prof. Me. José Luiz Leonardo de Araujo Pimenta – Instituto Nacional de Investigación Agropecuaria Uruguay
Prof. Me. José Messias Ribeiro Júnior – Instituto Federal de Educação Tecnológica de Pernambuco
Profª Drª Juliana Santana de Curcio – Universidade Federal de Goiás
Profª Ma. Juliana Thaisa Rodrigues Pacheco – Universidade Estadual de Ponta Grossa
Profª Drª Kamilly Souza do Vale – Núcleo de Pesquisas Fenomenológicas/UFPA
Prof. Dr. Kárpio Márcio de Siqueira – Universidade do Estado da Bahia
Profª Drª Karina de Araújo Dias – Prefeitura Municipal de Florianópolis
Prof. Dr. Lázaro Castro Silva Nascimento – Laboratório de Fenomenologia & Subjetividade/UFPR
Prof. Me. Leonardo Tullio – Universidade Estadual de Ponta Grossa
Profª Ma. Lillian Coelho de Freitas – Instituto Federal do Pará
Profª Ma. Liliani Aparecida Sereno Fontes de Medeiros – Consórcio CEDERJ
Profª Drª Lívia do Carmo Silva – Universidade Federal de Goiás
Prof. Dr. Lucio Marques Vieira Souza – Secretaria de Estado da Educação, do Esporte e da Cultura de Sergipe
Prof. Me. Luis Henrique Almeida Castro – Universidade Federal da Grande Dourados
Prof. Dr. Luan Vinicius Bernardelli – Universidade Estadual do Paraná
Prof. Dr. Michel da Costa – Universidade Metropolitana de Santos
Prof. Dr. Marcelo Máximo Purificação – Fundação Integrada Municipal de Ensino Superior

Prof. Me. Marcos Aurelio Alves e Silva – Instituto Federal de Educação, Ciência e Tecnologia de São Paulo

Profª Ma. Maria Elanny Damasceno Silva – Universidade Federal do Ceará

Profª Ma. Marileila Marques Toledo – Universidade Federal dos Vales do Jequitinhonha e Mucuri

Prof. Me. Ricardo Sérgio da Silva – Universidade Federal de Pernambuco

Profª Ma. Renata Luciane Polsaque Young Blood – UniSecal

Prof. Me. Robson Lucas Soares da Silva – Universidade Federal da Paraíba

Prof. Me. Sebastião André Barbosa Junior – Universidade Federal Rural de Pernambuco

Profª Ma. Silene Ribeiro Miranda Barbosa – Consultoria Brasileira de Ensino, Pesquisa e Extensão

Profª Ma. Solange Aparecida de Souza Monteiro – Instituto Federal de São Paulo

Prof. Me. Tallys Newton Fernandes de Matos – Faculdade Regional Jaguaribana

Profª Ma. Thatianny Jasmine Castro Martins de Carvalho – Universidade Federal do Piauí

Prof. Me. Tiago Silvio Dedoné – Colégio ECEL Positivo

Prof. Dr. Welleson Feitosa Gazel – Universidade Paulista

COVID-19 no Brasil os múltiplos olhares da ciência para compreensão e formas de enfrentamento 4

Editora Chefe: Profª Drª Antonella Carvalho de Oliveira
Bibliotecária: Janaina Ramos
Diagramação: Maria Alice Pinheiro
Correção: Mariane Aparecida Freitas
Edição de Arte: Luiza Alves Batista
Revisão: Os Autores
Organizador: Luís Paulo Souza e Souza

Dados Internacionais de Catalogação na Publicação (CIP)

C873 COVID-19 no Brasil os múltiplos olhares da ciência para compreensão e formas de enfrentamento 4 / Organizador Luís Paulo Souza e Souza. – Ponta Grossa - PR: Atena, 2020.

Formato: PDF

Requisitos de sistema: Adobe Acrobat Reader

Modo de acesso: World Wide Web

Inclui bibliografia

ISBN 978-65-5706-656-0

DOI 10.22533/at.ed.560200812

1. Epidemia. 2. Pandemia. 3. COVID-19. I. Souza, Luís Paulo Souza e (Organizador). II. Título.

CDD 614.5

Elaborado por Bibliotecária Janaina Ramos – CRB-8/9166

Atena Editora

Ponta Grossa – Paraná – Brasil

Telefone: +55 (42) 3323-5493

www.atenaeditora.com.br

contato@atenaeditora.com.br

DECLARAÇÃO DOS AUTORES

Os autores desta obra: 1. Atestam não possuir qualquer interesse comercial que constitua um conflito de interesses em relação ao artigo científico publicado; 2. Declaram que participaram ativamente da construção dos respectivos manuscritos, preferencialmente na: a) Concepção do estudo, e/ou aquisição de dados, e/ou análise e interpretação de dados; b) Elaboração do artigo ou revisão com vistas a tornar o material intelectualmente relevante; c) Aprovação final do manuscrito para submissão.; 3. Certificam que os artigos científicos publicados estão completamente isentos de dados e/ou resultados fraudulentos.

APRESENTAÇÃO

O ano de 2020 iniciou marcado pela pandemia da COVID-19 [*Coronavirus Disease 2019*], cujo agente etiológico é o SARS-CoV-2. Desde a gripe espanhola, em meados de 1918, o mundo não vivia uma crise sanitária tão séria que impactasse profundamente todos os segmentos da sociedade. O SARS-CoV-2 trouxe múltiplos desafios, pois pouco se sabia sobre suas formas de propagação e ações no corpo humano, demandando intenso trabalho de Pesquisadores(as) na busca de alternativas para conter a propagação do vírus e de formas de tratamento dos casos.

No Brasil, a doença tem se apresentado de forma desfavorável, com elevadas taxas de contaminação e de mortalidade, colocando o país entre os mais atingidos. Em todas as regiões, populações têm sido acometidas, repercutindo impactos sociais, sanitários, econômicos e políticos. Por se tratar de uma doença nova, as lacunas de informação e conhecimento ainda são grandes, sendo que as evidências que vão sendo atualizadas quase que diariamente, a partir dos resultados das pesquisas. Por isso, as produções científicas são cruciais para melhor compreender a doença e seus efeitos, permitindo que se pense em soluções e formas para enfrentamento da pandemia, pautando-se na cientificidade. Reconhece-se que a COVID-19 é um evento complexo e que soluções mágicas não surgirão com um simples “*estalar de dedos*”, contudo, mesmo diante desta complexidade e com os cortes de verbas e ataques de movimentos obscurantistas, os(as) Cientistas e as universidades brasileiras têm se destacado neste momento tão delicado ao desenvolverem desde pesquisas clínicas, epidemiológicas e teóricas, até ações humanitária à população.

Reconhecendo que, para entender a pandemia e seus impactos reais e imaginários no Brasil, devemos partir de uma perspectiva realista e contextualizada, buscando referências conceituais, metodológicas e práticas, surge a proposta deste livro. A obra está dividida em diversos volumes, elencando-se resultados de investigações de diversas áreas, trazendo uma compreensão ampliada da doença a partir de dimensões que envolvem alterações moleculares e celulares de replicação do vírus; lesões metabólicas que afetam órgãos e sistemas corporais; quadros sintomáticos; alternativas terapêuticas; efeitos biopsicossociais nas populações afetadas; análise das relações das sociedades nas esferas culturais e simbólicas.

Destaca-se que esta obra não esgota a discussão da temática [e nem foi pensada com esta intenção], contudo, avança ao permitir que os conhecimentos aqui apresentados possam se somar às informações já existentes sobre a doença. Este material é uma rica produção, com dados produzidos por diversos(as) Pesquisadores(as) de regiões diferentes do Brasil.

Sabemos o quão importante é a divulgação científica e, por isso, é preciso evidenciar a qualidade da estrutura da Atena Editora, que oferece uma plataforma consolidada e confiável para os(as) Pesquisadores(as) divulgarem suas pesquisas e para que os(as)

leitores(as) tenham acesso facilitado à obra, trazendo esclarecimentos de questões importantes para avançarmos no enfrentamento da COVID-19 no país.

Luís Paulo Souza e Souza

SUMÁRIO

CAPÍTULO 1..... 1

EMERGÊNCIA DE SAÚDE PÚBLICA: READEQUAÇÃO DOS SERVIÇOS DE SAÚDE EM TEMPOS DE COVID-19

Matheus Bresser
Ana Luísa Scafura da Fonseca
Ana Luíza de Castro Carvalho
Gabriel Vinícius Trindade de Abreu
Vinícius Cordeiro Martins
Adriana Vilella Ávila de Castro
José Antonio Chehuen Neto

DOI 10.22533/at.ed.5602008121

CAPÍTULO 2..... 13

PANDEMIA DE COVID-2019 E UM COMPARATIVO COM A MERS E SARS

Sara Cristine Marques dos Santos
Isabela Santos Moraes
Ivan Lucas Picone Borges dos Anjos
Tháís Lemos de Souza Macedo
Juliana de Almeida Silveira
Juliana Alves Costa
Tháísa Pimenta Ferreira de Oliveira
Gabriel de Lima Machado da Fonseca
Paulo Víctor Innocencio Póvoa de Castro
Esther Mathias Marvão Garrido Dias Salomão
Daniela Maria Ferreira Rodrigues
Ivana Picone Borges de Aragão

DOI 10.22533/at.ed.5602008122

CAPÍTULO 3..... 27

MÁSCARAS E A PANDEMIA POR COVID-19

Bruna Maliska Haack
Bruna Ventura Lapazini
Junir Antônio Lutinski
Vitor de Mello Netto

DOI 10.22533/at.ed.5602008123

CAPÍTULO 4..... 36

ENFRENTANDO A COVID-19: PRODUÇÃO DE UMA CARTILHA EDUCATIVA SOBRE AS PRINCIPAIS PANDEMIAS DA HISTÓRIA

Aline Carvalho da Silva
Andressa Karen Rodrigues Dantas
Ana Gabriele Santos da Veiga
Guilherme Araújo Silva
Keury dos Reis Valente
Merivalda Vasconcelos Lobato
Mikaellem Lima Gonçalves

Raquel Silva de Carvalho
Amanda Ouriques de Gouveia
Laís Araújo Tavares Silva

DOI 10.22533/at.ed.5602008124

CAPÍTULO 5.....45

A LUTA PARA MITIGAR DANOS CAUSADOS POR COVID19 MEDIANTE ESFORÇOS DAS FORÇAS MILITARES, PROFISSIONAIS DE SAUDE E ÓRGÃOS GOVERNAMENTAIS

Danízio Valente Gonçalves Neto
Elenildo Rodrigues Farias
Jair Ruas Braga
Erick de Melo Barbosa
José Guilherme de Almeida Sampaio
José Ricardo Cristie Carmo da Rocha
Milca Telles dos Santos
Raquel de Souza Praia
Nélio Gomes de Oliveira
Aline Campos Dinelly Xavier
Fabrício Ramos Rozas
Inez Siqueira Santiago Neta

DOI 10.22533/at.ed.5602008125

CAPÍTULO 6.....56

EMERGÊNCIA DE SAÚDE PÚBLICA DE IMPORTÂNCIA INTERNACIONAL RELACIONADA AO SARS-COV-2: UMA DISCUSSÃO SOBRE A IVERMECTINA, HIDROXICLOROQUINA, CLOROQUINA E NITAZOXANIDA

Alessandra Moreira de Oliveira
Vanessa Albertina Correia Gomes
Leandro Gabriel Ribeiro de Lima

DOI 10.22533/at.ed.5602008126

CAPÍTULO 7.....71

AVALIAÇÃO COGNITIVA E PSICOSSOCIAL RELACIONADAS À COVID-19 NA POPULAÇÃO BRASILEIRA: UMA EXPERIÊNCIA MULTIPROFISSIONAL EM SAÚDE

Arthur Oliveira Dantas
Carla Kalline Alves Cartaxo Freitas
Claudia Sordi
Fernanda Gomes de Magalhães Soares Pinheiro
Kelly Dayanne Oliveira Silva
Laila Santos Silva
Louise Moreira Rocha
Rafael Nascimento Santos
Roxane de Alencar Irineu
Scheila Farias de Paiva

DOI 10.22533/at.ed.5602008127

CAPÍTULO 8..... 74

USO DE EQUIPAMENTOS DE PROTEÇÃO INDIVIDUAL E MEDIDAS NÃO FARMACOLÓGICAS NO CENÁRIO DA PANDEMIA DO COVID-19: UMA REVISÃO INTEGRATIVA

Simone Souza de Freitas
Amanda Dacal Neves
Ana Beatriz Souza Nunes
Andryelle Rayane Coelho de Oliveira
Bárbara dos Santos Paulino
Daiany Bárbara Ornilio da Silva
Eveliny Silva Nobre
Heloise Agnes Gomes Batista da Silva
Iasmym Oliveira Gomes
José Roberto Marques Simões Júnior
Maria da Conceição de Oliveira Pinheiro
Matheus Lucas Vieira do Nascimento
Maiza Moraes da Silva
Reginaldo Luís da Rocha Júnior
Vitória Beatriz dos Santos Paulino

DOI 10.22533/at.ed.5602008128

CAPÍTULO 9..... 83

A CARTOGRAFIA TEMÁTICA NA REPRESENTAÇÃO DA DIFUSÃO DA COVID-19: ESTUDO DE CASO NO ESTADO DE SANTA CATARINA ENTRE 12/03/2020 E 09/08/2020

Vivian da Silva Celestino Reginato
André Felipe Bozio
João Victor Hernandes Vianna Lemos Nappi
Paulo Fernando Meliani

DOI 10.22533/at.ed.5602008129

CAPÍTULO 10..... 96

UM ESTUDO COMPARATIVO ENTRE ALEMANHA E ITÁLIA EM PERÍODOS ANTES E DURANTE A PANDEMIA DA COVID-19

Thyago José Arruda Pacheco
Marianne Teixeira Martins
Gustavo Soares Braga
Clarissa Melo Lima

DOI 10.22533/at.ed.56020081210

CAPÍTULO 11 107

ATUAÇÃO DO ENFERMEIRO RESIDENTE NOS CUIDADOS DE PACIENTE COVID-19 NA POSIÇÃO PRONA EM UNIDADE DE TERAPIA INTENSIVA (UTI)

Tamiris Moraes Siqueira
Mariza Quércio Machado
Carolina Fadoul de Brito
Danielle da Costa Marques Aponte
Índira Silva dos Santos
Ivanildes Gomes Petillo

Josias Mota Bindá
Leonardo Augusto Ferreira Nogueira
Milena Maria Cardoso de Lemos
Nairze Saldanha Santos da Silva
Orleane Rosas Mourão
Rogério Gomes Pereira

DOI 10.22533/at.ed.56020081211

CAPÍTULO 12..... 111

**A PANDEMIA PELO NOVO CORONAVÍRUS (SARS-COV-2) E A SEGURANÇA DOS
PROFISSIONAIS DE ENFERMAGEM**

Caren Franciele Coelho Dias
Cleide Monteiro Zemolin
Ezequiel da Silva
Caliandra Letiere Coelho Dias
Cristina Medianeira Gomes Torres
Aline Schifelbein da Rosa

DOI 10.22533/at.ed.56020081212

CAPÍTULO 13..... 118

**A PANDEMIA DA COVID-19 E SUAS CONSEQUÊNCIAS PARA A VIOLÊNCIA LABORAL
DEFERIDA À EQUIPE DE ENFERMAGEM**

Beatriz Vieira da Silva
Cláudia Fabiane Gomes Gonçalves
Wellington Tenório Cavalcanti Júnior
Jéssica Cabral dos Santos Silva
Jefferson Nunes dos Santos
Wendell Soares Carneiro
Silvana Cavalcanti dos Santos
Judicléia Marinho da Silva
Valdirene Pereira da Silva Carvalho
Romina Pessoa Silva de Araújo
Ana Karine Laranjeira de Sá
Cynthia Roberta Dias Torres Silva

DOI 10.22533/at.ed.56020081213

CAPÍTULO 14..... 126

A ATUAÇÃO DA FISIOTERAPIA NO COVID-19

Lara Laís de Carvalho Silva
Ana Mara Ferreira Lima
Andréia Patrícia de Brito
Aneilanna Carvalho Silva
Érica Maria de Oliveira Silva
Igor Cardoso Araújo
Juliana do Nascimento Costa
Layane Cardoso Lima
Maria Dayanne Cardoso de Lira
Renata Raniere Silva de Andrade

Thatylla Kellen Queiroz Costa

Camila Ribeiro Daniel

DOI 10.22533/at.ed.56020081214

CAPÍTULO 15..... 135

COMO ALIAR PANDEMIA, CIÊNCIA E COMUNIDADE?: RELATO DO CICLO DE PALESTRAS BENEFICENTE ON-LINE EM FSIOTERAPIA AQUÁTICA

Rute Pires Costa

Alexandre Luiz Albuquerque Pereira

Patrícia Linhares Colares Cavalcanti

Victor Hugo Souza Lustosa

Rômulo Nolasco Brito

Raquel Pires Costa

Túlio Leal Alves

DOI 10.22533/at.ed.56020081215

CAPÍTULO 16..... 141

OBESIDADE COMO FATOR DE RISCO NA INFECÇÃO POR SARS-COV-2: REVISÃO SISTEMÁTICA

Ana Carolina Cavalcante Viana

Anarah Suellen Queiroz Conserva Vitoriano

Synara Cavalcante Lopes

Carolina Frazão Chaves

Priscila da Silva Mendonça

Mileda Lima Torres Portugal

Líliá Teixeira Eufrásio Leite

Priscila Taumaturgo Holanda Melo

Renata Kellen Cavalcante Alexandrino

Helen Pinheiro

Lorena Taúsz Tavares Ramos

Ana Raquel Eugênio Costa Rodrigues

DOI 10.22533/at.ed.56020081216

CAPÍTULO 17..... 149

OS EFEITOS DA CLOROQUINA E HIDROXICLOROQUINA NO TRATAMENTO DA COVID-19 E SUAS REPERCUSSÕES CARDÍACAS

Juliana Alves Costa

Sara Cristine Marques dos Santos

Juliana de Almeida Silveira

Rayane de Oliveira Silva Santos

Anna Carolina Varanda Frutuoso

Laura Avraham Ribas

Ariane Luiza de Siqueira Braga

Brenda Alves Fernandes

Paulo Roberto Hernandez Júnior

Bruno Pereira Siqueira

Patrícia Pereira Nogueira

Ivana Picone Borges de Aragão

DOI 10.22533/at.ed.56020081217

CAPÍTULO 18..... 161

HISTORICAL OVERVIEW OF SARS-COV-2 INFECTION AND THE INFLUENCE OF ACE INHIBITORS, ARBs, IBUPROFEN AND CORTICOIDS

Caio Teixeira dos Santos
Raul Ferreira de Souza Machado
Géssica Silva Cazagrande
Flávia Pina Siqueira Campos de Oliveira
Jenifer Rocha Balbino
Marianna Ramalho de Sousa
Tarcila Silveira de Paula Fonseca
Silvério Afonso Coelho Velano
Lívia Soares Viana
Júlia Alonso Lago Silva
Ivana Picone Borges de Aragão

DOI 10.22533/at.ed.56020081218

CAPÍTULO 19..... 177

O VEGANISMO EM TEMPOS DE COVID-19: UMA PRÁTICA FILOSÓFICA RECOMENDÁVEL

Danielle Brandão de Melo
Thalita Marques da Silva

DOI 10.22533/at.ed.56020081219

CAPÍTULO 20..... 181

LEVANTAMENTO DO IMPACTO DO COVID-19 SOBRE ACOMETIMENTOS HEPÁTICOS PRÉ-EXISTENTES E ANÁLISE DAS REPERCUSSÕES FUTURAS

Aiko Iwamoto
Patricia do Rocio Litça
Mariana Yamamoto Wollmann
Djanira Aparecida da Luz Veronez

DOI 10.22533/at.ed.56020081220

CAPÍTULO 21..... 195

REVISÃO INTEGRATIVA: O ALEITAMENTO MATERNO DEVE SER MANTIDO EM CASOS DE COVID-19?

Fernanda Milagres Resende Chitarra
Natália Oliveira Izidoro
Luiza Carvalho Babo de Resende
Daiane Vaz Coelho
Guilherme Augusto Netto Nacif
Amanda Sabino dos Santos
Ana Cláudia Rodrigues Ferreira
Alícia Müller Fregulia
Thais Campino Siqueira
Ramon Silva Fortes
Milena de Oliveira Simões
Fillipe Laignier Rodrigues de Lacerda

DOI 10.22533/at.ed.56020081221

SOBRE O ORGANIZADOR.....	207
ÍNDICE REMISSIVO.....	208

CAPÍTULO 18

HISTORICAL OVERVIEW OF SARS-COV-2 INFECTION AND THE INFLUENCE OF ACE INHIBITORS, ARBS, IBUPROFEN AND CORTICOIDS

Data de aceite: 01/12/2020

Data de submissão: 02/09/2020

Júlia Alonso Lago Silva

Universidade de Vassouras, Vassouras-Rio de Janeiro <http://lattes.cnpq.br/6161980191599045>

Ivana Picone Borges de Aragão

Universidade de Vassouras, Vassouras-Rio de Janeiro <http://lattes.cnpq.br/3776867916156668>

Caio Teixeira dos Santos

Universidade de Vassouras, Vassouras-Rio de Janeiro <http://lattes.cnpq.br/7116724405914364>

Raul Ferreira de Souza Machado

Universidade de Vassouras, Vassouras-Rio de Janeiro <http://lattes.cnpq.br/2252865417019046>

Géssica Silva Cazagrande

Universidade de Vassouras, Vassouras-Rio de Janeiro <http://lattes.cnpq.br/4912820931997057>

Flávia Pina Siqueira Campos de Oliveira

Universidade de Vassouras, Vassouras-Rio de Janeiro <http://lattes.cnpq.br/8902544020831664>

Jenifer Rocha Albino

Universidade de Vassouras, Vassouras-Rio de Janeiro <http://lattes.cnpq.br/2422056656043320>

Marianna Ramalho de Sousa

Universidade de Vassouras, Vassouras-Rio de Janeiro <http://lattes.cnpq.br/3887826096786978>

Tarcila Silveira de Paula Fonseca

Universidade de Vassouras, Vassouras-Rio de Janeiro <http://lattes.cnpq.br/4663918547499182>

Silvério Afonso Coelho Velano

Universidade de Vassouras, Vassouras-Rio de Janeiro <http://lattes.cnpq.br/0501797679120149>

Lívia Soares Viana

Universidade de Vassouras, Vassouras-Rio de Janeiro <http://lattes.cnpq.br/4774722921409491>

ABSTRACT: The SARS-CoV-2 was first identified in China and later spread to several continents. The worldwide concern is the high transmissibility of the virus due to the form of contagion being interpersonal, through nasal and oral aerosol by coughing, sneezing, or speaking, besides they can be deposited on objects and remain for hours or days. The objective is to report an update of the literature data on COVID-2019 and the use of drugs such as ibuprofen, corticosteroids, and ACE inhibitors. Descriptive exploratory literature review. Success in controlling spread depends primarily on public health measures, informing and preventing transmission, such as contact isolation. Clinical manifestations range from common cold to severe pneumonia. The main symptoms are fever, unproductive cough, and dyspnea. The elderly, those with comorbidities and immunosuppressed are at risk for complications. The SARS-CoV-2 uses the angiotensin-converting enzyme (ACE) present in endothelium, lungs, and kidneys to bind to the target cells. ACE inhibitors or ARBs increase ACE enzyme expression. ECA2 expressed on the superficial spikes of the virus can be amplified by ibuprofen. Corticosteroids can stop or slowing the progression of infections, but immunosuppression

and hyperglycemia increase mortality. It is not recommended to interrupt ACE inhibitors due to the benefits. As a symptomatic treatment, other anti-inflammatory drugs should be used replacing ibuprofen and patients using corticoids for indication should not have their use suspended, but their initiation should be discouraged.

keywords: Infecções por Coronavirus; Ibuprofeno; Sistema Renina-Angiotensina; Angiotensina II; Corticosteroides.

KEYWORDS: Coronavirus infections; Ibuprofen; Renin-Angiotensin System; Angiotensin II; Corticosteroids.

RESUMO: O SARS-CoV-2 foi identificado pela primeira vez em 2019 na China e, posteriormente, se disseminou para os vários continentes. A preocupação mundial é a alta transmissibilidade do vírus devido à forma de contágio ser interpessoal, por meio de aerossol nasal e oral, provenientes da tosse, fala e espirro, além de ser depositado em objetos e permanecer por horas ou dias. O objetivo foi relatar uma atualização dos dados da literatura sobre o COVID-2019 e o uso de drogas como ibuprofeno, corticosteróides e inibidores da ECA. Revisão descritiva da literatura exploratória. O sucesso no controle da disseminação depende principalmente de medidas de saúde pública, informando e impedindo a transmissão, como o isolamento de contatos. As manifestações clínicas variam de resfriado comum a pneumonia grave. Os principais sintomas são febre, tosse improdutiva e dispnéia. Os idosos, aqueles com comorbidades e imunossuprimidos estão em risco de complicações. O SARS-CoV-2 usa a enzima conversora de angiotensina (ECA) presente no endotélio, pulmões e rins para se ligar às células-alvo. Inibidores da ECA ou BRA aumentam a expressão da enzima da ECA. O ECA2 expresso nos picos superficiais do vírus pode ser amplificado pelo ibuprofeno. Os corticosteróides podem parar ou retardar a progressão das infecções, mas a imunossupressão e a hiperglicemia aumentam a mortalidade. Não é recomendado interromper os inibidores da ECA devido aos benefícios. Como tratamento sintomático, outros medicamentos anti-inflamatórios devem ser utilizados em substituição ao ibuprofeno e os pacientes em uso de corticóide para indicação não devem ter seu uso suspenso.

PALAVRAS - CHAVE: Infecções por Coronavirus; Ibuprofeno; Sistema Renina-Angiotensina; Angiotensina II; Corticosteroides.

INTRODUCTION

In December 2019, the first cases of “pneumonia of unknown etiology” were registered in Wuhan city, China. [1] The patients manifested fever over 38°C, pneumonia characteristic radiological examination findings, normal or reduced leukocyte count or lymphopenia, without a satisfactory response to 3 to 5-day administered antimicrobial therapy. [2] The seafood market exposure was identified as a common factor among patients with respiratory conditions. [3]

On December 31st, 2019, 59 suspect cases were transferred to a designated hospital where lower respiratory tract samples were collected (bronchoalveolar lavage) and on January 3rd, 2020, the new coronavirus (SARS-CoV-2) were identified and confirmed as a pathogen causing a set of acute respiratory conditions, now called as Coronavirus

Disease-19 (COVID-19). [4, 5, 6]

With an average incubation period of 4 days, great transmissibility of COVID-19 was identified, as a factor of great concern worldwide. A high level of interpersonal contagion has been identified from infected individuals, through droplets and aerosols from the mouth and nose during coughing, sneezing, or speaking, which can remain active and infectious on surfaces or objects for a period of 2 to 7 days. [1.7]. Consequently, in March 2020, the World Health Organization (WHO) characterized the disease as a pandemic. [8]

Although infection by the new coronavirus has a very wide clinical manifestation, ranging from a simple cold to severe pneumonia, this new virus has not yet fully clarified its spectrum. The main clinical symptoms are respiratory origins, such as dry cough and dyspnea, fever, myalgia, fatigue, shock, acute respiratory distress syndrome, acute or renal cardiac injury, secondary infection, and death. Laboratory tests commonly found in hospitalized patients include lymphocytopenia, thrombocytopenia, and leukopenia, elevated C-reactive protein, chest X-ray with signs of pneumonia [1,2,5, 9]

The diagnosis is made by collecting secretion from the lower respiratory tract, through sputum or bronchoalveolar lavage, and superior, through nasopharyngeal aspiration or oral swab [10] between the third and the seventh day after the onset of viral symptoms. The technique used for virus detection is through the polymerase chain reaction (RT-PCR - Reverse transcription-polymerase chain reaction) or positive serology for COVID-19. [11]

The disease due to COVID-19 infection is generally mild, especially for children and young adults. However, it can have a severe course in about 1 in 5 infected people in need of hospital care. [7] The median age of infected and clinically symptomatic patients who were diagnosed was 49 to 56 years.

The intensity of viral replication, associated with the development of lung injury due to the disease, contributes to making the group of patients with chronic diseases at higher risk, among them are the elderly, smokers, cardiovascular diseases, diabetes mellitus, chronic lung diseases, cancer and other diseases immunosuppressive drugs, and the consequent need for admission to the intensive care unit. [12] SARS-CoV-2 infection may contribute to the destabilization of cardiovascular diseases previously compensated by the increase in oxygen consumption generated by the disease. There seems to be a higher incidence of case reports in biologically male individuals. [13]

According to the American College of Cardiology (ACC), among patients hospitalized for COVID-19, 50% had chronic diseases and 40% had cardiovascular or cerebrovascular disease. [14]

In a study carried out with 41 hospitalized patients and with infection confirmed by laboratory tests with the new coronavirus in Wuhan, 49% of the patients were between 25 and 49 years old and 34% between 50 and 64 years old, with an average age of 49, 0 years. In this study, no child or adolescent was infected. Of the 41 patients, 32% were admitted to the ICU (Intensive Care Unit) because they needed a high-flow nasal cannula or higher-

level oxygen support measures to correct the hypoxemia. Most of the infected patients were male (73%); less than half had underlying diseases (32%), including diabetes (20%), hypertension (15%), and cardiovascular disease (15%). [4]

Another study with 138 laboratory-confirmed patients with COVID-19 showed that 64 (46.4%) had one or more coexisting medical conditions. Hypertension, diabetes, and cardiovascular disease were the most common coexisting conditions. [5]

Patients over 60 years old, with comorbidities such as diabetes and heart disease and children at perinatal age, are the group most likely to develop Acute Respiratory Failure Syndrome, and consequently, need treatment in the ICU. [15]

The COVID-19 pandemic has resulted, so far, in more deaths compared to the sum of both, Severe Acute Respiratory Syndrome (SARS) of 2002, originating in China and spreading worldwide with more than 8,000 infected and about 800 deaths, and the Middle East Respiratory Syndrome (MERS) 2012 [16], originating in Saudi Arabia spread to the Middle East, Europe, and Africa with 2,266 cases and 804 deaths from WHO. [17.18]

The use of antihypertensive drugs, especially angiotensin-converting enzyme inhibitors (ACE inhibitors) and specific angiotensin blockers (BRAs), as well as drugs with anti-inflammatory power such as ibuprofen and glucocorticoids, have been widely discussed in the current world scenario, since they are widely used drugs and, several times, for the treatment of pathologies in which their suspensions can be very harmful to sick individuals. As a result, knowing what is in the recent literature about the use of these drugs and their possible interactions with COVID-19 is of great relevance for clinical practice.

Thus, the objective of the present study is to evaluate the influence of drugs such as ACE inhibitors, ARBs, ibuprofen, and corticosteroids on coronavirus infection, responsible for the current pandemic.

METHODS

This is an exploratory-descriptive study reviewed the literature with articles selected from MEDLINE US National Library of Medicine / National Institutes of Health MedLine (PubMed / NIH), Scientific Electronic Library Online (SciELO), Latin American and Caribbean Health Sciences (LILACS) - Latin American and Caribbean Health Information Center / Pan American Health Organization / World Health Organization (Regional Library of Medicine / BIREME / PAHO / WHO) and USE Library System (SIBI-USP) published between 1995 and 2020 in English, Portuguese and Spanish languages. The following descriptors were used for the search: Coronavirus infections; Ibuprofen; Renin-Angiotensin system; Angiotensin II; Corticosteroids. Fifty-three publications were viewed.

LITERATURE REVIEW

In different historical moments, other viral pandemic disseminations by respiratory

ways in humans demonstrated high mortality rates by cardiovascular complications, supplanting all the other causes, including pneumonia and other respiratory outcomes. SARS and MERS caused myocarditis and promptly progressing heart failure, evidencing the heart diseases' development potential, including acute coronary event by rupture of atherosclerotic plaque and acute myocardial infarct. [19.20]

Analysis of interactions between the virus and its receptors generates predictive data for the new infection based on prior knowledge of other strains. Current studies have shown the presence interaction between the SARS-CoV, responsible for the 2002 outbreak, and the SARS-CoV-2 related to the surface protein receptor connection: several research lines demonstrated infection by SARS-CoV is determined by the affinity between the viral surface protein and host ACE2 connecting, initially, in the fixing step. The specific amino acids in positions 442, 472, 479, 480, and 487 intensify the viral connection to ACE2. When all fragments that favor ACE2 are combined with the viral surface protein, the virus enters the human cell. Of the 14 fragments contained in the SARS-CoV viral surface, 9 are completely maintained and 4 are partially maintained in SARS-CoV-2, determining similarity in contamination form. The evolutive relation between SARS-CoV is well established and both viruses use the ACE2 receptor to infect lung host cells. [20] It is worth noting, however, that the SARS-CoV-2 receptor binding domain has a greater affinity for ACE2 compared to SARS-CoV. [21]

The COVID-19 infection has its main origin in the respiratory tract, possibly causing acute respiratory infections, although there are also reports of the gastrointestinal tract, related to the inhibition of ACE (angiotensin-converting enzyme). [22] Coronaviruses are single tape RNA viruses, which have a protein anchored in their envelope that first performs a connection to the receptor to the host cell, right after the interaction, occurs the fusion of the cell membranes. This connection occurs through a mandatory domain receiver (RDB), which has a central structure, the receptor-binding motif (RBM), which recognizes the ACE receptor in the host, attaching itself to its external surface. [23]

The angiotensin-converting enzyme (ACE) and its counterpart ECA2, belongs to the ACE2 family of dipeptidyl carboxypeptidases, however, they have two opposite physiological functions. ACE cleaves angiotensin I to generate angiotensin II (the peptide that binds and activates AT1 to constrict the blood vessel and thereby raising blood pressure), whereas ECA2, inactivates angiotensin II by generating angiotensin 1-7 (which has function vasodilator through activation of its Mas receptor). It thus acts as a negative body renin-angiotensin regulator. [21]

The protein similarity between the SARS-CoV-2 and SARS-CoV viruses is 76 - 78%. Thus, the sequence equality between the viral surface proteins suggests the possible compatibility between the same receptor. The viral protein surface fragments correspond to amino acids. The 493 fragment of SARS-CoV-2 corresponds to the 479 fragment of SARS-CoV and both represent asparagine, which removes the unfavorable interaction and

improves viral connection to human ACE2. Besides that, SARS-CoV-2 Gln493 is compatible with hotspot-31, suggesting that the coronavirus can recognize ACE2 and infect human cells. Fragment 487 corresponds to threonine, which strengthens structural stability and also leads to favorable interaction with ACE2, improving the viral connection to man, configuring a critical function in transmission. [23]

Fragments 455, 486, and 494 correspond to leucine, phenylalanine, and serine, respectively, and assist in the binding of the viral protein with the angiotensin II converting enzyme, although the binding is not as intense as the fragments mentioned above. Among them, phenylalanine (Phe486) is the strongest and most favorable interaction, facilitating the recognition of human cells. It is important to point out that structural analysis warns of a greater capacity for infection from the mutation of fragment 501 of SARS-CoV-2 (487 - SARS-CoV), increasing the chances of contamination of patients, who must be well monitored in the face of infectious condition. [23]

Use of Renin-Angiotensin-Aldosterone System Inhibitors

The renin-angiotensin-aldosterone system (RASA) is capable of contributing significantly to hydro electrolytic homeostasis, blood pressure (BP) control, regulation of metabolic processes, and modulation of the growth and cell proliferation of various tissues, being involved in several physiological or pathophysiological processes. Its main components are renin, angiotensinogen, ECA, ECA2, angiotensins, and the receptors that mediate their actions. [24]

SRAA acts especially on arterial regulation, having its main actions performed by angiotensin II, vasopressor peptide, and growth factor activity in the cardiovascular system. This is formed by the hepatic angiotensinogen cleavage by an enzyme cascade initiated by renin, which is mainly renal in synthesis, which converts it to angiotensin I. [25] This conversion occurs when there is a drop in blood pressure, which leads to cleavage of the pro-renin in juxtaglomerular cells, with consequent release of renin. [26] Then, due to the action of ACE, Angiotensin I catalyzes into Angiotensin II, mainly through the passage of blood in the lungs, intestine, kidneys, and blood vessels, where ACE is expressed by endothelial cells. [27]

During the short stay of Angiotensin II in the blood, it works by raising blood pressure through direct vasoconstriction of the arterioles, generating an increase in peripheral vascular resistance, in addition to reducing the levels of renal excretion of water and sodium, which configures the ability to promote slower and longer-lasting effects of pressure increase [26], enhanced by the reduction of aldosterone secretion (secondarily increasing sodium and water retention) and the activation of the sympathetic nervous system that releases catecholamines. By inhibiting ACE, the transformation of angiotensin I into angiotensin II is inhibited, inhibiting all its effects. Also, ACE degrades bradykinin, a potent endogenous vasodilator, and natriuretic substance; consequently, the inhibition of this enzyme enhances

the effects of this peptide. [28]

The ACE2 ectoenzyme is opposed to ECA's actions. In this sense, even though ECA2 is homologous to ACE, ACE inhibitors and ARBs are not able to inhibit their activity, on the contrary: both ACE inhibitors and ARBs seem to increase ECA2 expression. [29]

ACE inhibitors are important antihypertensives that act by preventing the transformation of angiotensin I into II in the blood and tissues, being effective in the treatment of arterial hypertension in hyperemic patients. [27] Currently, these drugs are widely used not only in the treatment of high blood pressure but in other cardiovascular diseases (or associated with them) such as heart failure; myocardial infarction; type 2 diabetes; kidney failure, and diabetic nephropathy. [30]

As the ARBs are capable of acting on both systolic and diastolic pressure and promote pressure control making it impossible for angiotensin II to come into contact with AT1 receptors, preventing the action of blood pressure elevation by vasoconstriction and the release of aldosterone by the adrenals, which causes water retention. [31] The blockage of the AT1 receptor culminates in an increase of renin and angiotensin I and II in the blood and tissues, which leads to greater stimulation of AT2 and MAS receptors promoting vasodilation by increasing bradykinin and nitric oxide, natriuresis and inhibits cellular growth. In these conditions, the AT2 receptors receive a greater amount of connections and the MAS receptors are more stimulated by the increase in the angiotensin peptide. [32]

Therefore, it can be seen that the angiotensin-converting enzyme plays an important role in cardiovascular system pathologies. The expression of this enzyme is greater in patients with cardiovascular diseases such as hypertension and diabetes, [27] once the angiotensin-converting enzyme inhibition treatment increases the enzymatic expression.

SARS-CoV-2 appears to not only obtain initial entry through ECA2 but also to sub-regulate its activity, rendering the enzyme unable to exert protective effects on the organs. It has been postulated, but not proven, that the unshakable activity of angiotensin II may be partly responsible for organ damage in Covid-19. Negative regulation of ACE2 activity in the lungs facilitates the initial infiltration of neutrophils and may result in unopposed angiotensin II accumulation and local activation of RAAS. Deregulated ACE2 can also attenuate cardioprotection in the context of myocardial impairment and abnormal pulmonary hemodynamics in Covid-19. Myocardial injury markers are elevated during Covid-19 disease and increase rapidly with clinical deterioration and premature death. [33.34]

The lower activity of ACE results in increased expression of this enzyme, which favors viral infection and increases the risk of severe forms, [35] playing a fundamental role in the disease caused by coronavirus and other types of viruses, such as influenza; the coronaviruses that cause severe acute respiratory syndrome use ECA2, present in the endothelium, lungs, and kidneys, to bind to the target cells, allowing greater exposure and predisposition of patients with cardiovascular pathologies to SARS-CoV-2 contamination. [14] In addition, specific amino acids have been identified that enhance viral binding to

ECA2 between the new coronavirus and human receptors, however, these are less efficient compared to SARS-CoV binding affinity. [23.36]

After a study inducing myocardial infarction in rats, it was found that ARBs increase cardiac expression of ACE2 three times after chronic treatment (28 days). Besides, it can be seen that losartan positively regulates renal ECA2 expression and that higher levels of ECA2 in the urine have been observed in patients with hypertension treated with olmesartan. Such data thus suggest that chronic AT1 blockade results in positive regulation of ACE2 in rats and humans. [21]

Under epidemiological parameters, new research shows that pre-existing cardiovascular disease increases the risk of COVID-19 infection: 15% of hospitalized patients had hypertension, and 15% also had a cardiovascular disease in Wuhan, China, at the outbreak of cases in January 2020. Also, among patients who developed severe conditions, such as coronavirus pneumonia, 40% developed associated cerebrovascular disease. Thus, it is concluded that patients with cardiovascular risk should be more monitored than those who do not have cardiovascular pathologies. [14]

However, these drugs should not be discontinued. In addition to the lack of proven clinical evidence on the use of ACEI / BRA in complications or fatal conditions caused by COVID19, its benefits cannot be disregarded. These drugs not only reduce symptoms but alter the natural history of the disease, reducing mortality from arterial hypertension and the occurrence of serious outcomes, such as stroke and acute myocardial infarction, in addition to being able to change prognosis, decrease the risk of decompensation and delaying the decline in renal function in patients with nephropathies. [37]

There is a clear potential for damage related to the withdrawal of RAAS inhibitors in patients in stable condition, and Covid-19 is particularly severe in patients with underlying cardiovascular diseases and, in many of these patients, active myocardial injury, myocardial stress, and cardiomyopathy develop during the disease. Therefore, until additional data is available, RAAS inhibitors should be continued in patients in stable conditions who are at risk. [33.38]

It is also worth noting that some studies point to the possibility that ARBs may provide some protection against severe lung injury, as observed in animal tests. [39] Many studies on SARS-CoV, probably also relevant to the current epidemic, suggest that binding of the coronavirus surface protein to ECA2 leads to negative regulation of ECA2 production, that is, decreases its production. Consequently, there is excessive production of angiotensin, since the body understands that there is a lack of this due to the low conversion resulting from the lower amount of ACE2. The excess of circulating angiotensin, in turn, stimulates the greater expression of the AT1 receptor, which contributes to lung injury since it generates increased pulmonary vascular permeability. Given the above, it can be seen that a higher expression of ACE2 could, paradoxically, protect infected individuals against acute lung injury

This can be explained by some mechanisms: the blockage of excessive AT1 activation

mediated by angiotensin caused by a viral infection, preventing the exacerbated increase in pulmonary vascular permeability; the regulation of ECA2, which reduces the production of angiotensin by ACE and thereby increases the production of the vasodilator angiotensin [21]; the anti-fibrotic function of ACE2 in Severe Acute Respiratory Syndrome, caused by desquamation of pneumocytes and destruction of the hyaline membrane, resulting from the pulmonary action of COVID-19. [39]

Thus, the use of losartan can be protective in the face of this complication, despite the need for proof by tests on live animals. [39] It is noteworthy that, although calcium channel blockers do not reduce the mortality of patients with heart failure and coronary artery disease (CAD), they can be an alternative to the treatment of hypertension and cardiovascular diseases, since this class of drug does not demonstrate ECA2 performance. [27]

Use of Ibuprofen

Regarding anti-inflammatory activity, ibuprofen and corticosteroids are widely used drugs that have important consequences concerning its use in COVID-19 patients.

Ibuprofen is a drug of the nonsteroidal anti-inflammatory group (NSAID) used to treat pain, fever, and inflammation. They act by competitively inhibiting arachidonic acid by the active center of enzymes cyclooxygenases 1 and 2, thus avoiding the consequent formation of pro-inflammatory mediators by this route. [40].

When there is a harmful stimulus to the tissue, whether chemical, physical, or biological, there is the release of several inflammatory mediators, such as prostaglandins, histamine, serotonin, and other peptides, such as angiotensin, substance P and bradykinin. Besides, the harmful process triggers tissue acidosis, with the production of potassium and hydrogen ions. [41]

This acute inflammatory reaction causes morphological and vascular changes and promotes the formation of cellular infiltrate at the site of the injury. Besides this release of inflammatory mediators, there is direct cellular injury by the release of intracellular enzymes and activates the complement system. All of these changes lead to selective sensitization by algic substances (mainly prostaglandins, serotonin, and bradykinin). [41]

Prostaglandin is the most important inflammatory substance, the main ones being I2, E1 and E2, generating not only pain, but fever, since they act on the hypothalamus, increasing body temperature, and the local inflammatory stimulus itself, by increased neutrophil chemotaxis to the site of inflammation. The great mediator of the formation of the inflammatory substances cited is the enzyme cyclooxygenase (COX). Thus, anti-inflammatory substances act as central and peripheral enzyme inhibitors of COX, and therefore they prevent and considerably reduce the release of these substances. Ibuprofen, in particular, as well as other drugs such as paracetamol and dipyron, has greater power to inhibit the release of Prostaglandin E, being more effective as antipyretics, since this prostaglandin is

the main modulator of body temperature. [41]

This drug is classified as a non-selective COX inhibitor, inhibiting both constitutional COX-1 and COX-2, induced only by the inflammatory process and by IL1, IL2, and TNF α interleukins. Because it also inhibits COX 1, responsible for the production of constitutional prostaglandins that participate in the secretion of gastric mucus to protect gastric cells and thus presents an increased risk of gastrointestinal side effects, it is a drug with reversible effect. [41]

This medicine, as well as ACE inhibitors and ARBs, also increase ACE2 levels, since angiotensin is one of the substances released when tissue injury occurs. Thus, its use is reported to increase the risk of serious infection. [41]

There is no evidence of interactions or side effects, but its use is believed to facilitate infection, since ACE2, expressed in the superficial spicules of the virus, can be amplified by Ibuprofen. [27]

Non-steroidal anti-inflammatory drugs (NSAIDs), including Ibuprofen, prolong the duration of acute inflammatory diseases, especially respiratory ones. Due to the inhibitory effect on cyclooxygenases, there is less recruitment of polymorphonuclear cells and inhibition of the synthesis of lipoxins and resolvins, generating a sluggish immune system and perpetuated infection [42].

Ibuprofen and other anti-inflammatory drugs also cause exacerbation of serious pathologies, such as acute myocardial infarction, in addition to complications such as cerebrovascular [43] and nephrotoxic events. NSAIDs have also been associated with complicated pneumonia and pleural effusion. Specifically in SARS-CoV-2 infection, anti-inflammatories exacerbate the activity of the water and sodium regulatory enzyme in the body, in addition to contributing to the development of pneumonia [44]. Due to the similarity between COVID-19 and SARS - CoV - 2, it is believed that there is the same effect in both diseases.

Although there is no specific evidence for the use of Ibuprofen and other NSAIDs in patients affected by COVID-19, observational data suggest that the use of NSAIDs can be harmful to the patient due to the effects mentioned above. Paracetamol, on the other hand, had fewer side effects and greater resolution in acute respiratory diseases, being, therefore, the advisable drug for these cases. [45] Thus, WHO initially recommended not to use this drug for the symptomatological treatment of COVID-19 infection. However, other anti-inflammatory drugs such as dipyron and paracetamol may be alternatives until further studies are carried out. [46.47]

Use of Corticosteroids

Glucocorticoids are synthetic substances that simulate the effect of the cortisol hormone. The drug, free in plasma or interstitial fluid, penetrates the cell and binds to the cytoplasmic receptor, where it interacts with the receptor complex + HSP 90 to be transported

to the nucleus. After binding, it dissociates from HSP 90 and the receptor-ligand complex is actively transported to the nucleus, where it interacts with DNA, like most hormones. [41] Then, changes occur in the transcription of certain genes, inhibiting some and stimulating others, inducing the synthesis of anti-inflammatory proteins and other proteins that act on systemic metabolism. [48]

One of the important effects of this class of drugs is its anti-inflammatory and immunosuppressive capacity, radically reducing the manifestations of inflammation through deep COX inhibition effects and on the concentration, distribution, function, and chemotaxis of peripheral leukocytes, in addition to suppressive effects on inflammatory chemokines and other lipid and glycolipid mediators of inflammation. [41]

The immunosuppressive activity of these drugs is important for stopping or slowing the progression of pneumonia and is effective in the treatment of respiratory distress syndrome. In addition to playing an anti-inflammatory role to reduce systemic inflammation, decrease exudative fluid in lung tissue, promote absorption and prevent further diffuse alveolar damage, which can alleviate hypoxemia and effectively protect the lung to prevent the progression of respiratory failure. It can also induce a decrease in body temperature and help relieve symptoms of hyperthermia. [49]

Regardless of the benefits associated with the use of corticosteroids, complications induced by treatment, such as secondary infection (fungi and bacteria) and hyperglycemia should be valued. Current studies, although inconclusive, suggest increased mortality and secondary infection rates in influenza, decreased clearance of SARS-CoV and MERS-CoV, and complications of therapy with corticosteroids. [50.51]

The use of corticosteroids was considered a therapeutic option for other coronaviruses in addition to COVID-19. In SARS, hydrocortisone was used in a group of patients without comorbidities or evidence of respiratory failure and recent onset of symptoms by SARS-CoV. There was evidence of the widening of the viral replication phase, with detectable RNA in the plasma at 12 days for those who used hydrocortisone versus 8 days for the placebo. [52]

In MERS-CoV, hydrocortisone was used in patients considered critical and the persistence of detectable viral RNA in plasma was also observed. Corticosteroid therapy was not associated with higher mortality, but most studies obtained inconclusive results as to the degree of recommendation for its use, with a small percentage of studies as unsatisfactory results.[53]

CONCLUSIONS

The SARS-CoV infection is determined by the affinity between the host's viral surface protein and ACE2, the highest affinity being the SARS-CoV-2 receptor binding by ACE2 compared to SARS-CoV. Given the previously established benefits of ACE inhibitors and

ARBs, so far there has been no recommendation for discontinuation due to the absence of data proving superiority in their discontinuation, and effective follow-up of these patients is oriented.

Among the non-steroidal anti-inflammatory drugs, the use of Ibuprofen should be replaced by others to relieve pain or inflammation by increasing ACE2 levels due to the release of angiotensin in tissue injury. There is no evidence of interactions or side effects, but its use is believed to facilitate infection, since ACE2, expressed in the superficial spicules of the virus, can be increased by Ibuprofen.

The use of corticoids should not be immediately suspended in patients with clinical indications but should be discouraged as initial therapy and/or in those without clinical indications that justify its usage. Treatment-induced complications such as secondary infection (fungi and bacteria) and hyperglycemia should be valued. Studies suggest increased mortality and secondary infection rates in influenza, SARS-CoV, and MERS-CoV.

REFERENCES

1. Wei-jie G, Zheng-yi N, Yu H, Wen-hua L, Chun-quan O, Jian-xing H, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* [internet] 2020 Feb [access in 2020 Mar 30]. Available in: <https://www.nejm.org/doi/full/10.1056/NEJMoa2002032>.
2. Qun L, Xuhua G, Peng W, Xiaoye W, Lei Z, Yeqing T, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. *N Engl J Med* 2020 Jan;382(13):1199-1207.
3. Liangsheng Z, Fu-ming S, Fei C, Zhenguo L. Origin and Evolution of the 2019 Novel Coronavirus. *Clinical Infectious Diseases*. *Clinical Infectious Diseases* [internet]2020 Feb [access in 2020 Mar 30]. Available in: <https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa112/5721420>
4. Chaolin H, Yeming W, Xingwang L, Lili R, Jianping Zhao, Yi H, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020 Feb; 395:497-506.
5. Dawei W, Bo H, Chang H, Fangfang Z, Xing L, Jing Z, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *Jama* 2020 Feb; 323(11):1061-1069
6. Na Z, Dingyu Z, Wenling W, Xingwang L, Bo Y, Jingdong S, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med* 2020 Feb; 382:727-733.
7. Lewis R. Coronavirus Stays in Aerosols for Hours, on Surfaces for Days. *Medscape Medical News*; 2020 Mar 17.
8. Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *Lancet* 2020 Mar; 395(10226):809-815.
9. Ebrahim SH, Ahmed QA, Gozzer E, Schlagenhauf P, Memish ZA. Covid-19 and community mitigation strategies in a pandemic. *BMJ* 2020 Mar; 368:m1066.

10. Ministério da Saúde. Protocolo de Manejo Clínico para o Novo Coronavírus (2019-nCoV). Brasília. Ministério da saúde; 2020.

11. Char L. Clinical features of deaths in the novel coronavirus epidemic in China. *Rev Med Virol* 2020 Feb; e2103.

12. Ministério da saúde. Plano de Contingência para Epidemia da Doença pelo Coronavírus 2019 (COVID-19) do Distrito Federal. Diretoria de Vigilância Epidemiológica e Gerenciamento De Epidemiologia De Campo; 2020.

13. Sáfadi MAP. Novo coronavírus (COVID-19). Departamento Científico de Infectologia; 2020. Report, 14.

14. Li C, Guang H. The Role of Angiotensin Converting Enzyme 2 in Coronaviruses/Influenza Viruses and Cardiovascular Disease. SSRN [internet] 2020 Feb [access in 2020 Mar 30]. Available in https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3537961 .

15 Cai H. Sex difference and smoking predisposition in patients with COVID-19. *Lancet Respir Med* 2020 Mar; 11(20).

16. Secretária da Saúde de São Paulo [Internet Homepage]. Coronavírus. Centro de Vigilância Epidemiológica: Doenças de Transmissão Respiratória [Access in 2020 Mar 17]. Available in: <http://www.saude.sp.gov.br/resources/cve-centro-de-vigilancia-epidemiologica/areas-de-vigilancia/doencas-de-transmissao-respiratoria/coronavirus.html>

17. Saúde dos viajantes [Internet Homepage]. Síndrome respiratória do Oriente Médio – Novo coronavírus (MERS-CoV) [Access in 2020 Mar 17]. Available in: <http://www.saudedoviajante.pr.gov.br/2018/12/79/Sindrome-respiratoria-do-Oriente-Medio-Novocoronavirus-MERS-CoV-.html>

18. American College of Cardiology. COVID-19 Clinical Guidance For the Cardiovascular Care Team. *Clinical Bulletin*; 2020 Mar.

19. Lopes GQ. O impacto do coronavírus nas doenças cardiovasculares. *Portal PebMed* [internet]. 2020 March [Access in 2020 Mar 17]; Available in: <https://pebmed.com.br/o-impacto-do-coronavirus-nas-doencas-cardiovasculares/>

20. Munster VJ, Koopmans M, Doremalen NV, Riel DV, de Wit E. A Novel Coronavirus Emerging in China — Key Questions for Impact Assessment. *N Engl J Med* 2020 Feb; 382:692-694.

21. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. *Drug Dev Res* [internet] 2020 Mar [access in 2020 Mar 30]. Available in: <https://www.ncbi.nlm.nih.gov/pubmed/32129518>.

22. Zhonglin L, Tao B, Ling Y, Xiaohua H. Discovery of potential drugs for COVID-19 based on the connectivity map. *Research Square* [internet] 2020 Feb [access in 2020 Mar 30]. Available in: <https://www.researchsquare.com/article/rs-15242/v1>

23. Wan Y, Shang J, Graham R, Baric RS, Li F.J. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. *J of Virol* 2020 Mar; 17:94(7).

24. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. *Journal of Internal Medicine*. 2008;264(3):224-236.
25. Ribeiro JM, Florêncio LP. Bloqueio farmacológico do sistema renina-angiotensina-aldosterona: inibição da enzima de conversão e antagonismo do receptor AT1. *Rev Bras Hipertens* 2020 Jul/Sep; 7(3).
26. Hall JE, Guyton AC. *Guyton & Hall - Tratado de fisiologia médica*. 13ªed. Rio de Janeiro: Elsevier; 2017
27. Fang L, Karakoulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. *Lancet Respiratory Medicine* [internet] 2020 Mar [access in 2020 Mar 30]. Available in: [https://www.thelancet.com/journals/lanres/article/PIIS2213-2600\(20\)30116-8/fulltext](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30116-8/fulltext).
28. Ribeiro W, Muscará MN. Características farmacocinéticas de antagonistas de cálcio, inibidores da ECA e antagonistas de angiotensina II em humanos. *Rev Bras Hipertens* 2001 Jan/Mar; 8(1): 114-124.
29. Sanjuliani AF, Torres MRS, Paula LN, Bassan FB. Eixo Renina-Angiotensina-Aldosterona: bases fisiológicas e fisiopatológicas. *Rev HUPE* 2011;10(3):20-30. Available in: <https://www.e-publicacoes.uerj.br/index.php/revistahupe/article/view/8857/6743>
30. Carvalho MHC, Colaço AL, da Silva LBB, Salgado COM. Aspectos farmacológicos dos inibidores da ECA e dos receptores de angiotensina II. *Rev Bras Hipertens* 2005 Apr/Jun; 12(2): 97-102.
31. Filho HV. HAS - Antagonista da Angiotensina II: Droga de 1 ou 2 escolha?. *Rev Soc de Cardiologia do Rio Grande do Sul* 2007 May/Ago; 11.
32. Moraes A, Gonzaga C, Júnior OP. Qual o melhor bloqueio do sistema renina angiotensina aldosterona na hipertensão?. *Rev Bras Hipertens* 2013 Jun; 20(2):63-72.
33. Vaduganathan M, Vardeny O, Michel T, McMurray J, Pfeffer M, Solomon S. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. *New England Journal of Medicine*, [online] 2020; 382(17), pp.1653-1659. Available in: <https://www.nejm.org/doi/full/10.1056/NEJMSr2005760>
34. Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?. *Journal of Hypertension* [Internet]. 2020; 38(5):781-782. Available in: https://journals.lww.com/jhypertension/FullText/2020/05000/Can_angiotensin_receptor_blocking_drugs_perhaps_be.2.aspx
35. Sociedade Brasileira de Cardiologia [homepage na internet]. Nota de Esclarecimento: Infecção pelo Coronavírus 2019 (COVID-19) [access in 2020 Mar 17]. Available in: <http://www.cardiol.br/sbcinforma/2020/20200313-comunicado-coronavirus.html>.
36. Zhang H, Penninger JM, Li Y, et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive Care Med*, 2020 Mar; 46:586-590.
37. Sociedade Beneficente Israelita Brasileira [Internet Homepage]. Coronavírus (COVID-19): o que sabemos e o que esperar da nova infecção respiratória [access in 2020 Mar 17]. Available in: <https://www.hospitalsiriolibanes.org.br/coronavirus/Paginas/coronavirus.aspx>.

38. Comunicados oficiais, Sociedade Espanola de Cardiologia [Internet Homepage]. No hay evidencia clínica ni científica para suspender tratamientos de IECA y ARA debido a la infección por COVID-19 [access in 2020 Mar 17]. Available in: <https://secardiologia.es/institucional/socios/comunicados/comunicados-oficiales/11446-no-hay-evidencia-clinica-ni-cientifica-para-suspender-tratamientos-de-ieca-y-ara-debido-a-la-infeccion-por-covid-19>.
39. Zeinalian M, Salari-Jazi A, Jannesari A, Khanahmad H. A potential protective role of Losartan against coronavirus induced lung damage [letter]. Cambridge University Press 2020 Mar: 1-6.
40. Seabra CIR. Farmacocinética do Ibuprofeno. Porto. Dissertação [Mestrado em Ciências Farmacêuticas] – Universidade Fernando Pessoa, 2015.
41. Brunton LL, Chabner BA, Knollmann BC. Goodman & Gilman: As Bases Farmacológicas da Terapêutica. 12^a ed. Rio de Janeiro, McGraw-Hill, 2012.
42. Little P. Non-steroidal anti-inflammatory drugs and covid-19. BMJ [internet] 2020 mar 27; 368: m1185. [Access in 2020 April 26]. Available in: <https://www.bmj.com/content/368/bmj.m1185>
43. Wen YC, Hsiao FY, Lin ZF, Fang CC, Shen LJ. Risco de acidente vascular cerebral associado ao uso de anti-inflamatórios não esteróides durante o episódio de infecção respiratória aguda. Farmacoepidemiologia e segurança de medicamentos 2018; 27 (6): 645-651.
44. Day M. Covid-19: European drugs agency to review safety of ibuprofen. BMJ [internet] 2020 Mar 23; 368: m1168. [Access in 2020 April 26]. Available in: <https://www.bmj.com/content/368/bmj.m1168.long>
Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ 2020 Mar; 368:m1086.
45. Conselho Federal de Enfermagem [Internet Homepage]. OMS recomenda não usar ibuprofeno para tratar Covid-19 [access in 2020 Mar 17]. Available in: http://www.cofen.gov.br/oms-recomenda-nao-usar-ibuprofeno-para-tratar-covid-19_77961.html.
46. Conselho Federal de Enfermagem [Internet Homepage]. OMS revê recomendação de não usar ibuprofeno para tratar Covid-19 [access in 2020 Mar 17]. Available in: http://www.cofen.gov.br/oms-reve-recomendacao-de-nao-usar-ibuprofeno-para-tratar-covid-19_77961.html
47. Anti SMA, Giorgi, RDN, Chahade, WH. Antiinflamatórios hormonais: glicocorticoides. Einstein 2008; 6(1), 159-165.
48. Yin W, Weiwei J, Qi H, Cheng W, Baoju L, Pan Z, et al. Early, low-dose and short-term application of corticosteroid treatment in patients severe COVID-19 pneumonia: single-center experience from Wuhan, China. MedRxiv [internet] 2020 Mar [access in 2020 Mar 30]. Available in: <https://www.medrxiv.org/content/10.1101/2020.03.06.20032342v1.full.pdf+html>
49. Russel CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet 2020 Feb; 395(10223):473-475.
50. Calvo C, García MLH, Carlos JCV, Vázquez JLM. Recomendaciones sobre el manejo clínico de la infección por el «nuevocoronavirus» SARS-CoV2. Anales de Pediatría [internet] 2020 Mar [access in 2020 Mar 30]. Available in: <https://www.analesdepediatria.org/es-recomendaciones-sobre-el-manejo-clinico-avance-S169540332030076X>.

51. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. *J Clin Virol* 2004; 31: 304–09 [Access in 2020 April 26]. Available in: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108318/>

52. Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. *Am J Respir Crit Care Med* 2018; 197: 757–67] [Access in 2020 April 26]. Available in: <https://www.ncbi.nlm.nih.gov/pubmed/29161116>

ÍNDICE REMISSIVO

A

Aleitamento Materno 16, 195, 196, 197, 201, 204, 205

Angiotensina II 162, 174

Autocuidado 27, 40

C

Cardiologia 15, 149, 150, 153, 160, 174

Cartografia Temática 13, 83, 85

Cirurgia Geral 1, 3

Cloroquina 12, 15, 19, 56, 59, 60, 61, 64, 65, 67, 149, 150, 151, 152, 153, 156, 157, 158, 159, 160

Comportamento de Risco à Saúde 182

Coronavírus 14, 4, 9, 11, 13, 14, 15, 23, 24, 27, 29, 32, 33, 34, 39, 40, 44, 57, 59, 60, 61, 65, 69, 75, 80, 81, 84, 85, 86, 90, 91, 93, 94, 95, 96, 97, 98, 101, 110, 111, 112, 113, 115, 116, 117, 120, 124, 125, 126, 127, 128, 129, 132, 134, 136, 142, 144, 145, 146, 148, 153, 158, 160, 173, 174, 178, 180, 182, 186, 191, 196, 203, 207

Coronavírus da Síndrome Respiratória do Oriente Médio 14, 15, 97

Corticosteroides 162

Covid-19 2, 9, 10, 11, 12, 13, 14, 15, 16, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 17, 18, 19, 20, 21, 22, 23, 24, 25, 27, 28, 29, 30, 31, 32, 33, 34, 36, 37, 39, 40, 42, 43, 45, 46, 47, 48, 49, 53, 54, 55, 56, 57, 60, 61, 62, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 104, 105, 106, 107, 108, 109, 114, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 139, 140, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 163, 164, 165, 167, 168, 169, 170, 171, 172, 173, 174, 175, 177, 178, 179, 180, 181, 182, 183, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 201, 202, 203, 204, 205, 207

D

Densidade de Kernel 83

E

Economia 41, 136, 177, 179, 180

Ensino 33, 38, 42, 45, 135, 136, 137, 138, 140

Epidemiologia 81, 83, 124, 147, 173, 193

Equipamento de Proteção Individual 51, 75, 77, 79, 115

Equipe de Enfermagem 14, 118, 119, 120, 121, 122, 123, 125

Estilo de Vida 177, 179, 180, 181, 182, 183, 188

Excesso de peso 142, 146, 192

F

Fígado 17, 63, 128, 129, 181, 182, 183, 185, 186, 187, 188, 189, 190

Fisioterapia 14, 126, 127, 130, 131, 132, 134, 135, 137, 138, 139

Fisioterapia Respiratória 127, 131, 132

H

Hepatopatias 182, 184, 185, 186, 190

Hidroterapia 136

Hidroxicloroquina 12, 15, 19, 56, 58, 59, 61, 63, 64, 67, 149, 150, 151, 153, 158, 159, 160

I

Ibuprofeno 162, 175

Infecções por Coronavírus 14, 15, 72, 108, 119, 162

Isolamento Social 6, 28, 32, 72, 80, 94, 113, 120, 181, 183, 187, 190

Ivermectina 12, 55, 56, 57, 58, 61, 62, 63, 67

L

Lesão por pressão 108

M

Método Coroplético 83, 86

N

Nitazoxanida 12, 56, 60, 61, 65, 66, 67

O

Obesidade 15, 15, 18, 141, 142, 144, 145, 146, 147, 179, 181, 184, 185, 186, 188, 189, 190

P

Pandemia 9, 11, 13, 14, 15, 1, 3, 4, 5, 6, 7, 8, 9, 13, 17, 18, 27, 28, 29, 30, 31, 32, 33, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 53, 55, 57, 67, 71, 72, 73, 74, 75, 76, 79, 80, 81, 83, 84, 85, 86, 91, 94, 96, 97, 98, 101, 102, 103, 104, 111, 112, 113, 117, 118, 119, 120, 121, 122, 123, 124, 127, 135, 136, 137, 138, 139, 140, 142, 145, 149, 150, 151, 152, 154, 158, 177, 178, 179, 180, 181, 182, 183, 185, 186, 187, 188, 191, 204, 205

Pandemias 11, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 55, 72, 104, 111, 120, 177, 180

Pessoal de saúde 111

Prevenção 3, 8, 9, 15, 19, 27, 31, 32, 41, 43, 47, 49, 63, 76, 81, 111, 112, 113, 115, 116, 120, 124, 127, 130, 131, 140, 145, 148, 152

Promoção da saúde 27

S

SARS-COV-2 9, 12, 14, 15, 16, 2, 9, 10, 11, 12, 13, 14, 16, 17, 18, 20, 25, 26, 28, 33, 35, 44, 45, 46, 56, 57, 58, 59, 60, 61, 62, 63, 64, 68, 69, 72, 75, 78, 84, 96, 97, 101, 104, 105, 111, 112, 115, 116, 120, 136, 141, 142, 143, 145, 146, 147, 149, 150, 151, 154, 155, 157, 158, 161, 162, 163, 165, 166, 167, 170, 171, 173, 174, 178, 187, 193, 196, 198, 201, 202, 204, 205

Saúde Mental 43, 72, 73, 204

Serviços de Saúde 11, 1, 3, 4, 81, 111, 113, 115, 116, 119, 122, 123, 124, 147

Síndrome Respiratória Aguda Grave 13, 14, 15, 57, 59, 84, 108, 132, 145, 150, 196, 197

Sistema de Defesa Nuclear, Biológico, Químico, Radiológico 45, 47

Sistema Renina-Angiotensina 162, 174, 189

T

Tecnologia Educacional 36, 37, 38, 39, 41, 42, 136

Telemedicina 1, 3, 4, 5, 9

U

Unidades de Terapia Intensiva 1, 3, 6, 87, 109, 133


V


Veganismo 16, 177, 178, 179, 180

Violência no Trabalho 118, 119, 120, 121, 122, 123

***COVID-19 no Brasil:
Os Múltiplos Olhares da Ciência
para Compreensão e Formas de
Enfrentamento***

4

www.atenaeditora.com.br 

contato@atenaeditora.com.br 


[@atenaeditora](https://www.instagram.com/atenaeditora) 

www.facebook.com/atenaeditora.com.br 

***COVID-19 no Brasil:
Os Múltiplos Olhares da Ciência
para Compreensão e Formas de
Enfrentamento***

4

www.atenaeditora.com.br 

contato@atenaeditora.com.br 

[@atenaeditora](https://www.instagram.com/atenaeditora) 

www.facebook.com/atenaeditora.com.br 